We aimed to investigate the potential cardiovascular risk of anti-immunoglobulin(Ig)-E (omalizumab) and anti-interleukin(IL)-5/IL5 receptor (IL5R) therapies (mepolizumab and benralizumab) in patients with severe asthma compared with non-biologic users. Here, IL5RA is linked to asthma.